TherapeuticsMD Files 8-K on Security Holder Vote Matters

TL;DR

TXMD filed an 8-K for a security holder vote - watch for updates on corporate actions.

AI Summary

On December 5, 2024, TherapeuticsMD, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, incorporated in Nevada, is involved in the pharmaceutical preparations industry.

Why It Matters

This filing indicates that TherapeuticsMD is seeking approval or has held a vote on significant matters concerning its security holders, which could impact corporate governance or strategic decisions.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a vote by security holders and does not inherently present new financial or operational risks.

Key Players & Entities

• TherapeuticsMD, Inc. (company) — Registrant
• Nevada (jurisdiction) — State of Incorporation
• December 5, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.001 — ch Registered Common Stock, par value $0.001 per share TXMD The Nasdaq Stock Mar

Filing Documents

• ea0223856-8k_therap.htm (8-K) — 38KB
• 0001213900-24-106095.txt ( ) — 209KB
• txmd-20241205.xsd (EX-101.SCH) — 3KB
• txmd-20241205_lab.xml (EX-101.LAB) — 33KB
• txmd-20241205_pre.xml (EX-101.PRE) — 22KB
• ea0223856-8k_therap_htm.xml (XML) — 4KB

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. On December 5, 2024, TherapeuticsMD, Inc., a Nevada corporation (the "Company"), held its 2024 Annual Meeting (the "Annual Meeting"). At the close of business on October 17, 2024, the record date for the determination of stockholders entitled to vote at the Annual Meeting, there were 11,532,432 shares of the Company's common stock, par value $0.001 per share ("Common Stock"), outstanding and entitled to vote at the Annual Meeting. The holders of 6,832,199 shares of Common Stock were represented virtually or by proxy at the Annual Meeting, constituting a quorum. At the Annual Meeting, the stockholders of the Company considered and voted on proposals to: (1) elect four directors to serve until the Company's next annual meeting of stockholders or until their successors are duly elected and qualified; (2) approve, on a non-binding advisory basis, the compensation of the Company's named executive officers for the fiscal year ended December 31, 2023; and (3) ratify the appointment of Berkowitz Pollack Brant Advisors + CPAs, LLP, an independent registered public accounting firm, as the independent auditor of the Company for the fiscal year ending December 31, 2024. Set forth below are the final voting results for each proposal submitted to a vote of the stockholders at the Annual Meeting. For more information on the following proposals, see the Company's Definitive Proxy Statement on Schedule 14A, filed with the United States Securities and Exchange Commission on October 25, 2024. Proposal 1 : All of the four nominees for the Company's Board of Directors were elected to serve until the Company's next annual meeting of stockholders or until their successors are duly elected and qualified, by the votes set forth in the table below: Nominee For Withheld Broker Non-Votes Tommy G. Thompson 4,599,014 259,277 1,973,908 Cooper C. Collins 4,730,129 128,162 1,973,908 Gail K. Naughton, Ph.D. 4,635

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 5, 2024 THERAPEUTICSMD, INC. /s/ Marlan Walker Marlan Walker Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR